

Family/Last name

Date of birth

Given name(s)

Patient identifiers

Date of request

Accession/Laboratory number

All molecular elements are NON-CORE.[DATASET SCOPE](#) [OVERVIEW OF SELECTED MOLECULAR MARKERS](#) **ADEQUACY OF SPECIMEN FOR MOLECULAR ASSESSMENT** 

Specimen is adequate for analysis

Specimen is inadequate for analysis, *give reason, (select all that apply)*

Crush

Autolysis

Cautery

Necrosis

Decalcification

Tumour cell quantity

▼ Fixation issues, *specify*▼ Other, *specify***BRAF ALTERATIONS** **BRAF mutation**

Absent

Cannot be determined

BRAF V600E (c.1799T>A) mutation present

Other BRAF mutation present, *specify*

MUTATIONS ASSESSED (select all that apply)

V600E

Any mutation in exon 15

▼ Other, *specify*

TESTING METHOD (select all that apply)

Sanger sequencing

Next-generation sequencing

PCR-based method

▼ Other, *specify***ATRX MUTATION** **ATRX mutation**

Negative

Cannot be determined

Positive

TESTING METHOD (select all that apply)

Sanger sequencing

Next-generation sequencing

PCR-based method

▼ Other, *specify***ATRX expression (immunohistochemistry)**

Intact nuclear expression

Cannot be determined

Loss of nuclear expression

BRAF V600E expression (immunohistochemistry)

Negative

Cannot be determined

Positive

BRAF rearrangement/duplication

Absent

Cannot be determined

Present, *specify*

MUTATIONS ASSESSED (select all that apply)

7q34 tandem duplication

KIAA-BRAF fusion

BRAF-RAF1 fusion

▼ Other, *specify*

TESTING METHOD (select all that apply)

In situ hybridization (FISH)

RT-PCR

Array-based method

RNA-sequencing

▼ Other, *specify*

CDKN2A/B HOMOZYGOUS DELETION 

Absent Cannot be determined
 Homozygous deletion
 Heterozygous deletion

TESTING METHOD (select all that apply)
 In situ hybridization (FISH, CISH)
 Array-based method
 Next-generation sequencing
 ▼ Other, *specify*

CHROMOSOME 7 GAIN (combined with chromosome 10 loss) 

Absent Cannot be determined
 Present

TESTING METHOD (select all that apply)
 In situ hybridization
 Array-based method
 Next-generation sequencing
 ▼ Other, *specify*

C19MC ALTERATION 

Absent Cannot be determined
 Absent with low level gain
 Present, *specify, including copy number*

TESTING METHOD (select all that apply)
 In situ hybridization (FISH, CISH)
 Array-based method
 Next-generation sequencing
 ▼ Other, *specify*

CHROMOSOME 10q23 (PTEN LOCUS) DELETION AND PTEN MUTATION **Chromosome 10q23 (PTEN Locus) deletion**

None detected Cannot be determined
 Interstitial deletion present
 Monosomy, *specify*

▼ Polysomy, *specify*

TESTING METHOD (select all that apply)
 In situ hybridization
 Array-based method
 PCR/Loss of heterozygosity assay
 ▼ Other, *specify*

PTEN mutation

Absent Cannot be determined
 Present, *specify*

TESTING METHOD (select all that apply)
 Sanger sequencing
 Next-generation sequencing
 PCR-based method
 ▼ Other, *specify*

CHROMOSOMAL ARM 1p/19q CODELETION 









None detected Cannot be determined
 1p/19q codeletion
 1p only deletion
 19q only deletion
 Polysomy, *specify*

TESTING METHOD (select all that apply)
 In situ hybridization (FISH, CISH)
 Array-based method
 PCR/Loss of heterozygosity assay
 Next-generation sequencing
 ▼ Other, *specify*

EGFR AMPLIFICATION AND EGFRvIII MUTATION **EGFR amplification**

Absent Cannot be determined
 Absent with low level gain
 Present, *specify, including copy number*

TESTING METHOD (select all that apply)
 In situ hybridization (FISH, CISH)
 Array-based method
 Next-generation sequencing
 ▼ Other, *specify*

<p>EGFRvIII mutation</p> <p>Absent Cannot be determined</p> <p>Present</p> <p>TESTING METHOD (select all that apply)</p> <p>Next-generation sequencing</p> <p>PCR-based method</p> <p>Immunohistochemistry</p> <p>▼ Other, <i>specify</i></p>	<p>Ki-67 IMMUNOHISTOCHEMISTRY </p> <p>Percentage of positive nuclei</p> <p>Cannot be determined</p>
<p>HISTONE H3 MUTATION AND H3 K27 TRIMETHYLATION (me3) </p> <p>Histone H3 gene family mutation</p> <p>Negative Cannot be determined</p> <p>Positive for K27M</p> <p>Positive for G34R or G34V</p> <p>Positive, for other H3 mutation, <i>specify</i></p> <p>▼</p> <p>TESTING METHOD (select all that apply)</p> <p>Sanger sequencing</p> <p>Next-generation sequencing</p> <p>PCR-based method</p> <p>▼ Other, <i>specify</i></p> <p>Histone H3 K27M expression (immunohistochemistry)</p> <p>Negative Cannot be determined</p> <p>Positive</p> <p>Histone H3 G34R expression (immunohistochemistry)</p> <p>Negative Cannot be determined</p> <p>Positive</p> <p>Histone H3 K27me3 expression (immunohistochemistry)</p> <p>Intact expression Cannot be determined</p> <p>Loss of expression</p>	<p>L1CAM EXPRESSION (IMMUNOHISTOCHEMISTRY) </p> <p>Negative Cannot be determined</p> <p>Positive</p>
<p>IDH1/IDH2 MUTATION </p> <p>IDH1/IDH2 mutation</p> <p>Absent Cannot be determined</p> <p>▼ Present, <i>specify</i></p> <p>TESTING METHOD (select all that apply)</p> <p>Sanger sequencing</p> <p>Next-generation sequencing</p> <p>PCR-based method</p> <p>▼ Other, <i>specify</i></p> <p>IDH1 R132H expression (immunohistochemistry)</p> <p>Negative Cannot be determined</p> <p>Positive</p>	<p>LIN28A EXPRESSION (IMMUNOHISTOCHEMISTRY) </p> <p>Negative Cannot be determined</p> <p>Positive</p>
<p>Version 1.0 Published August 2018</p>	<p>MEDULLOBLASTOMA IMMUNOHISTOCHEMISTRY </p> <p>β-catenin expression (immunohistochemistry)</p> <p>Absence of nuclear expression Cannot be determined</p> <p>Positive nuclear expression</p> <p>GAB1 expression (immunohistochemistry)</p> <p>Negative Cannot be determined</p> <p>Positive</p> <p>YAP1 expression (immunohistochemistry)</p> <p>Negative Cannot be determined</p> <p>Positive</p>
<p>International Collaboration on Cancer Reporting (ICCR)</p>	<p>MGMT PROMOTER METHYLATION </p> <p>Absent Cannot be determined</p> <p>Present</p> <p>TESTING METHOD (select all that apply)</p> <p>Methylation-specific PCR</p> <p>▼ Other, <i>specify</i></p>
<p>Page 3 of 5</p>	<p>MONOSOMY 6 </p> <p>Absent Cannot be determined</p> <p>▼ Present, <i>specify</i></p> <p>TESTING METHOD (select all that apply)</p> <p>In situ hybridization</p> <p>Multiplex ligation-dependend probe amplification (MLPA)</p> <p>Array-based method</p> <p>Microsatellite analysis</p>

MYC GENE FAMILY AMPLIFICATION (*MYC* and/or *MYCN*) 

Absent Cannot be determined
 Absent with low level gain
 Present, *specify, including copy number*



TESTING METHOD (select all that apply)

In situ hybridization (FISH, CISH)
 Array-based method
 Next-generation sequencing
 Other, *specify*

**NAB2-STAT6 FUSION** **NAB2-STAT6 fusion**

Negative Cannot be determined
 Positive

TESTING METHOD (select all that apply)

FISH
 Next generation sequencing
 Other, *specify*

**STAT6 expression (immunohistochemistry)**

Absence of nuclear expression Cannot be determined
 Positive nuclear expression

PITUITARY HORMONES AND TRANSCRIPTION FACTORS IMMUNOHISTOCHEMISTRY 

Tumour cells are reactive for (select all that apply)

Prolactin Cannot be determined
 Human growth hormone
 β-TSH
 β-FSH
 β-LH
 Alpha subunit
 ACTH
 PIT1
 TPIT
 SF1

Other, *specify***RELA FUSION** 

Negative Cannot be determined
 Positive

TESTING METHOD (select all that apply)

FISH
 Next generation sequencing
 Other, *specify*

**SMARCA4/BRG1 ALTERATION** **SMARCA4/BRG1 mutation**

Absent Cannot be determined
 Present, *specify*



TESTING METHOD (select all that apply)

Sanger sequencing
 Next-generation sequencing
 PCR-based method
 Other, *specify*

**BRG1 loss of expression (immunohistochemistry)**

Intact nuclear expression Cannot be determined
 Loss of nuclear expression

SMARCB1/INI1/HSNF5 ALTERATION **SMARCB1/INI1/HSNF5 mutation**

Absent Cannot be determined
 Present, *specify*



TESTING METHOD (select all that apply)

Sanger sequencing
 Next-generation sequencing
 PCR-based method
 Other, *specify*

**INI1 (BAF47) loss of expression (immunohistochemistry)**

Intact nuclear expression Cannot be determined
 Loss of nuclear expression

TERT PROMOTER MUTATION 

Absent Cannot be determined
 Hotspot mutation (C228T or C250T)
 Other mutation, *specify*



TESTING METHOD (select all that apply)

Sanger sequencing
 Next-generation sequencing
 PCR-based method
 Other, *specify*



TP53 MUTATION

TP53 mutation

Absent Cannot be determined

▼ Present, *specify*

EXONS ANALYSED

Exons 5-8

All exons

▼ Other, *specify*

TESTING METHOD (select all that apply)

Sanger sequencing

Next-generation sequencing

PCR-based method

▼ Other, *specify*

p53 expression (immunohistochemistry)

Negative or rare, lightly positive cells Cannot be determined

Intermediate (intermediate numbers of predominantly lightly positive cells)

Positive (diffuse and strong nuclear positivity)

OTHER FINDINGS

Other immunohistochemical findings, specify

Other molecular findings, specify test, testing method and findings

YAP1 FUSION

Negative Cannot be determined

Positive

TESTING METHOD (select all that apply)

FISH

Next generation sequencing

▼ Other, *specify*